Uncategorized

Insilico’s AI design engine bags deal with Korean biotech worth possible $2.5B+

Published

on

Insilico Medicine and SK Biopharmaceuticals will use generative AI to develop novel therapies for unspecified neuroimmune disorders.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version